

Domenico Sergi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6529979/publications.pdf>

Version: 2024-02-01

39
papers

782
citations

471509

17
h-index

552781

26
g-index

39
all docs

39
docs citations

39
times ranked

1381
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	2
2	The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	4.6	11
3	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	3.4	12
4	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	4.1	17
5	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	4.9	12
6	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	4.4	13
7	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	5.1	30
8	Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	2.6	12
9	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	3.4	22
10	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	3.3	16
11	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	2.5	4
12	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	4.6	30
13	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	4.1	12
14	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	4.4	9
15	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016, 231, 986-991.	4.1	12
16	Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 years or younger: Evidence from a historic cohort. <i>Cancer Biology and Therapy</i> , 2016, 17, 470-476.	3.4	6
17	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	2.5	11
18	Triple positive early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	1.8	33

#	ARTICLE	IF	CITATIONS
19	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 53.	17.0	32
20	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	7.7	83
21	Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. <i>Journal of Cellular Physiology</i> , 2015, 230, 1708-1712.	4.1	5
22	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 26.	8.6	15
23	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	7.7	13
24	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015, 368, 20-25.	7.2	17
25	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	1.8	14
26	Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Journal of Cancer</i> , 2014, 5, 398-405.	2.5	8
27	Emerging Biological Treatments for Uterine Cervical Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 86-97.	2.5	51
28	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	2.5	39
29	Immunologic treatments for precancerous lesions and uterine cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 29.	8.6	39
30	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 718-724.	5.3	20
31	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	2.5	24
32	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	2.5	19
33	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	1.8	11
34	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014, 5, 9619-9625.	1.8	35
35	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 67.	8.6	22
36	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 119-123.	2.5	32

#	ARTICLE	IF	CITATIONS
37	Docetaxel, oxaliplatin, and capecitabine (DOX) combination chemotherapy for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, e15065-e15065.	1.6	1
38	A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. Journal of Experimental and Clinical Cancer Research, 2011, 30, 39.	8.6	20
39	Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2009, 28, 34.	8.6	18